Embed Size (px)
Citation preview
1
Presented By -: Amol A PardeshiGuided By -: Mrs. MRP Rao
AISSMS COLLEGE OF PHARMACY
2
Introduction Mechanism of drug release Formulation components of an osmotic
delivery system Classification of ODDS Factors affecting drug release rate References
3
Osmotically controlled drug delivery systems utilize osmotic pressure for controlled delivery of active agent.
Osmotic pressure : It is colligative property of solution in which
a non-volatile solute is dissolved in a volatile solvent.
4
Pure water
Semi permeable membrane
Aqueous Solution
Of osmotic solutes
5
6
It is defined as passage of solvent into a solution through semi permeable membrane .
It can take place when a concentrated solution is separated from a less concentrated solution by a semi permeable membrane.
6
7
It involves osmosis of gastrointestinal fluid across the semi permeable membrane at a controlled rate.
Dissolution of drug & osmotic agent to produce a saturated drug solution within a tablet core.
As the no. of molecules in solution increases, the osmotic pressure within a tablet core increases.
Outer coating (semi permeable membrane) is rigid.
Therefore to reduce the osmotic pressure within the tablet, saturated drug solution is emitted from a tablet core through orifice.
8
The major formulation components of a typical osmotic delivery system include :
1. Drug 2. Osmotic agents 3. Semi permeable membrane
9
Osmotic components usually are ionic compounds consisting of either inorganic salts or hydrophilic polymers.
These materials maintain a concentration gradient across the membrane.
They also generate a driving force for the uptake of water and assist in maintaining drug uniformity in the hydrated formulation.
10
Compound or Mixture Osmotic pressure (atm)
Sodium chloride 356
Fructose 355
Potassium chloride 245
Sucrose 150
Dextrose 82
Potassium sulphate 39
Mannitol 38
Sodium phosphate tribasic
36
11
Semi permeable membrane has important role in controlling drug release.
Membrane must meet several performance criteria-:
1. Polymer must exhibit Sufficient wet strength and water permeability so as to attain water flux rate in the desired range.
2. Reflection coefficient (leakage of solute through membrane) should approach the limiting value of 1 .
12
3. Membrane should be biocompatible.
e.g. Cellulose esters like cellulose acetate, cellulose acetate butyrate, cellulose triacetate and ethyl cellulose and Eudragits.
13
Wicking agents -: - It has ability to draw water in to the porous
network of a delivery device - E.g. colloidal silicon dioxide, kaolin, titanium
dioxide, SLS, low molecular weight (PVP). Pore forming agents -:- These agents are particularly used in the
pumps developed for poorly water soluble drugs and in the development of controlled porosity osmotic pumps.
- These pore forming agents cause the formation of micro porous membrane.
- alkaline metal salts such as sodium chloride, sodium bromide, potassium chloride, potassium sulfate, potassium phosphate, etc.
14
Implantable osmotic pump. Oral osmotic pump.
Implantable systems further classified as-:1. For experimental use2. For human use
15
For experimental use -: ALZET- It is a miniature, implantable osmotic
pumps for laboratory animals. The pump are used to deliver homogenous
solutions or suspensions continuously at a controlled rate for extended period.
It consist of Drug reservoir, osmotic sleeve & semipermeable membrane.
16
17
Duros-: It is a miniature, implantable osmotic
pumps for long term , parenteral , delivery of drug in human.
It consist of an impermeable, titanium alloy cylinder capped on one end by semi permeable membrane & another end by orifice for drug delivery.
Interior of implant contains a polymeric piston that separates from drug reservoir.
18
19
These systems can be further classified as-: Single chamber osmotic system: - Elementary osmotic pump Multi-chamber osmotic systems: - push-pull osmotic pump Miscellaneous: - Controlled porosity osmotic pumps - Osmotic bursting osmotic pump - Effervescent activity-based osmotic systems- OROS- CT- L-OROS
20
Elementary osmotic pump -: It consist of an osmotic core containing drug
& if required osmotic agent , which is coated with semi permeable membrane .
When core imbibes water osmotically at a controlled rate through semi permeable membrane , forming a saturated drug solution.
The system delivers, via orifice, saturated drug solution.
2121
22
Push-pull osmotic pump: It is modified elementary osmotic pump. It is used to deliver both poorly water soluble &
highly water soluble drug at a constant rate. It is resembles a standard bilayer coated tablet. One (upper) layer contains drug (60-80% of tablet
wt.) in formulation of polymeric osmotic agent & other tablet excipients.
This polymeric osmotic agent has ability to form a suspension of drug in situ when this tablet layer imbibes water.
Other layer contains osmotic & colouring agent.
23
To increase the permeability of membrane , two layers of the membrane are applied on pumps.
The inner membrane is micro porous membrane, which is made up of cellulosic materials containing some water soluble pore forming agents.
Semi permeable membrane covers this layer. When system is placed in an aqueous
environment the soluble components dissolve, resulting in microporous membrane which provides greater flux of water into the system.
2424
25
This system is similar to elementary osmotic pump except the delivery orifice is absent.
When it is placed in an aqueous environment, water is imbibed and hydraulic pressure is built up inside until the wall ruptures and the contents are released to the environment.
Varying the thickness as well as area of the semipermeable membrane can control release of drug.
The system is useful to provide pulsated release of drug.
26
27
This is commercially important variation of EOP. Poorly soluble drug may precipitate at the pH of
gastric fluid, when such drug is delivered through osmotic pump it may precipitate on the orifice.
An effervescent compound ( potassium bicarbonate) can be incorporated to overcome this problem.
When delivered from the pump with the drug solution, the bicarbonate reacts with acid in the exterior environment generating carbon dioxide.
The expansion of gas dispenses the precipitated drug, and preventing the blockage of the orifice.
28
It is developed by Alza co-operation. It is used as a once or twice a day formulation
for targeted delivery of drugs to the colon It consist of an enteric coat, SPM & core. Core consist of two compartments - one compartment consist of drug near to
orifice. - Second compartment consist of osmopolymer
29
30
Liquid OROS controlled release systems are designed to deliver drugs as liquid formulations.
It combine the benefits of extended-release with high bioavailability.
These are of two types -: - L-OROS Soft cap - L-OROS Hard cap
31
The liquid drug formulation is present in a soft gelatin capsule, which is surrounded with the barrier layer, the osmotic layer, and semi permeable membrane.
A delivery orifice is formed through these three layers.
When the system is in contact with the aqueous environment, water is imbibed & results in the development of osmotic pressure inside the system forcing the liquid formulation to break through the hydrated gelatin capsule shell at the delivery orifice.
32
It is similar to L-OROS Soft cap. It is consists of a liquid drug layer, a barrier
layer, and an osmotic engine but present in a hard gelatin capsule.
Then it is coated with SPM.
33
34
Orifice size
Solubility
Osmotic Pressure
34
35
The size of the orifice must be larger than a minimum size (600µ), to minimize hydrostatic pressure.
This is necessary step in achieving zero order drug release.
The size of the orifice must be smaller than a maximum size (1 mm) , to minimize diffusional contribution to delivery rate.
35
36
Mechanical drill Laser drill Indentation Use of leachable substances in the
semipermeable coating e.g. controlled porosity osmotic pump
36
37
The tablets in which holes are to be formed are charged in the hopper.
The tablets drop by gravity into the slots of the rotating feed wheel and are carried at a predetermined velocity to the passageway forming station
The passageway forming station, each tablet is tracked by an optical tracking system.
During tracking, the beam is transmitted by the optical tracking mechanism onto the surface of the moving tablets
37
38
It moves with the moving tablets as the mirror oscillates clockwise.
The walls of the tablet absorb the energy of the beam and gets heated ultimately causing piercing of the wall thus forming orifice.
38
3939
40
The release rate depends on the solubility of the solute inside the drug delivery system.
Therefore, drugs should have sufficient solubility to be delivered by osmotic delivery.
Various solubility modifying approaches include:
- Use of swellable polymers - Use of wicking agents - Use of effervescent mixtures - Use of cyclodextrin derivatives - Use of alternative salt form
40
41
There is no requirement for the system to disintegrate for the release of drug to occur.
Delivery of drugs takes place in solution form, which is ready for absorption.
Delivery rate is independent of pH and outside agitation.
The in vivo delivery rate of drug is expected to be same as that in vitro.
Due to its zero order release profile it is used in early stages of drug research, such as drug screening, animal toxicology .
41
42
Special equipment is required for making an orifice in the system.
If the coating process is not well controlled there is a risk of film defects, which results in dose dumping.
Residence time of the system in the body varies with the gastric motility and food intake.
It may cause irritation or ulcer due to release of saturated solution of drug.
42
43
Elementary osmotic pump
Push-pull osmotic systems
43
Brand Name API
Efidac 24 Chlorpheniramine
Acutrim Phenylpropanolamine
Sudafed 24 Pseudoephedrine
Brand Name API
Ditropan XL ® Oxybutynin chloride
Procardia XL® Nifedipine
44
Implantable osmotic systems
Brand Name API
Viadur® Leuprolide acetate
Chronogesic™ Sufentanil
45
1. Parmar NS, Vyas SK ;Osmotic pump –A novel drug delivery system. In: Jain NK, editor. Advances in controlled & novel drug delivery.1st ed, 2005. Delhi :CBS publishers. p -18-35.
2. Wilson CG, Shah HK ;programmed drug delivery systems & the colon. In: Rathbone MJ, Handgraft J, Lane ME , editor. Modified release drug delivery technology. 2nd edition, Vol-1, USA :Informa Healthcare , p-329-330.
45
46
3. Sinko PJ . Nonelectrolyte . In : Sinko PJ editor. Martin’s Physical and Pharmaceutical Science . 5thed. Philadelphia : Lippincott Williams and Wilkins ;2006.p.124-137
4. Lordi NG. Sustained release dosage forms . In : Lachman L, Lieberman HA ,Kaing JL . 3rded. Mumbai :Varghese publishing house ; 1990.p.455
47
5. R. K. Verma, D. M. Krishna, S. Garg. Review article on Formulation aspects in the development of Osmotically controlled oral drug delivery systems , J. Control. Release, 79, 7-27; 2002.
48
Thank you
48
